Estrella Immunopharma receives Nasdaq deficiency notices for low equity and low bid price

Estrella Immunopharma, Inc.

Stockholders' equity of $746,286 as of Sep 30, 2024, below Nasdaq's $2.5M minimum.
Has until Jan 3, 2025 to submit a compliance plan; Nasdaq may grant up to 180-day extension.
Separate bid price deficiency: common stock below $1.00 for 30 consecutive business days; cure period until May 19, 2025.
Both deficiencies have no immediate effect on listing, but failure to regain compliance could lead to delisting.
Company evaluating options to regain compliance; no assurance of success.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.